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Introduction
Diseases related to cardiovascular, endocrine, pulmonary, and renal disorders remain the leading causes of death in the United States. 1 Collectively, these diseases create tremendous burdens for patients, caregivers, families, and the U.S. healthcare system. But despite the need for new therapies and improvements in existing treatments and preventive approaches, investment in these therapeutic areas is lagging relative to other conditions. 2 We previously reported these concerns relative to cardiovascular development, 3 which is also true of the other major chronic diseases outlined here ( Figure 1 ). 4 Although investment and development has declined, there is still a pipeline of novel R&D therapeutics, contradicting the notion that there is a relative shortage of new basic scientific ideas to underpin clinical advances. In oncology, better understanding of the genetics of cancer has been essential in moving the development of new therapeutic agents forward. In cardiovascular, renal, endocrine and pulmonary diseases, these advances have only mostly led to incremental developments in therapeutics. While the issues are multifactorial, the challenge is finding a balance between generating needed evidence for safety and efficacy, despite the burden of cost and efficiency that may drive innovation into other therapeutic areas.
This article summarizes a meeting of key stakeholders, including the Commissioner of the U.S. Food and Drug Administration (FDA), other FDA officials, and organizations focusing on cardiovascular, endocrine, pulmonary, and renal disciplines. Its purpose was to identify and discuss priority issues, establish areas of common interest, and explore opportunities for collaboration (Appendix).
Cross-Disciplinary Themes
There was widespread recognition that multiple priorities were broadly shared (Table 1) .
Because many therapies are only partially effective, there is a need for clear evidence that the benefits of a treatment outweigh its risks, evaluating comparative effectiveness, and implementing treatment strategies for subpopulations. Accordingly, there was consensus that a much more efficient, high-volume system is needed to generate reliable evidence at lower cost and encourage investment in new developments as well as treatment alternatives.
Data from clinical registries and patient experiences is one option to generate meaningful evidence. Although traditional randomized controlled trials (RCTs) are the gold standard for marketing and labeling approval, real-world evidence (RWE) generated from data collected during routine care and in other settings, coupled with methods spanning cluster randomization, individual randomization, and observational analysis, can supplement RCT findings in important ways. 5 Such evidence can be used to support expanded indications for use; understand therapeutic effects on populations (including pediatric populations) who are underrepresented or absent from traditional RCTs; to establish long-term safety and effects of therapies beyond usual trial follow-up; and in selected cases, to less expensively generate large sample sizes for preregistration trials when traditional methods have already collected data on thousands of patients exposed to a new product.
Novel study designs, including Bayesian, adaptive, and seamless clinical trial designs; a priori responder analyses; endpoint relationship modeling; and disease subtype information synthesis can also improve overall study efficiency and accelerate the matching of treatments to specific populations. 6, 7 FDA encourages a flexible approach to trial design, prioritizing efficiency while also considering disease severity and rarity and degree of unmet need. However, research in chronic diseases lags oncology and rare-disease specialties in applying novel methods.
A harmonized legal schema (encompassing statutory, regulatory, and subregulatory authority) will allow patient data to be used for multiple purposes without imposing excessive burdens on researchers while also facilitating patients' control over their data. Although use of data from clinical registries may be limited due to current regulations, a re-evaluation of such use provides value for regulatory decision-making and is a point for further discussion with other collaborators, including the FDA. Additionally, professional societies 9 and government entities should work together to ensure that EHR companies include appropriate, useable, and interoperable data fields to support evidence generation. As such companies' primary customers, large health systems should collaborate on requiring these qualities from their vendors.
In addition, implementing a learning health system that supports RWE and existing data sources to guide regulatory decision-making and practice guidelines is essential to improving outcomes. This would create an ecosystem that provides sustainability for registries by embedding registries into the fabric of care documentation. would also help address the lack of demographic diversity among investigators.
Patient-Centered Approaches

Tobacco Regulation
The FDA deeming rule on tobacco regulation, which extends the agency's authority to regulate products such as electronic cigarettes, hookahs, selective cigars, and pipe tobacco, is strongly supported across therapeutic specialties. 12 Given rapid increases in electronic nicotine delivery systems (ENDS) use among middle-school and high school students, youth access to these products is concerning. [13] [14] [15] [16] Whether ENDS may serve as a harm-reduction strategy for adult smokers is unresolved, but research directly addressing this issue will require substantial time 17 while ENDS, hookah, and little cigar/cigarillo use among adolescents and teenagers continues.
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From 2012-2014, there were >7,500 distinct flavorings available for e-cigarettes on the Internet, with >200 added every month. 19 The FDA is encouraged to accelerate research efforts funded by the Tobacco User Fees to guide regulation of ENDS.
A related issue is the need to ban mentholated cigarettes. Two FDA advisory councils found that menthol additives make cigarettes less harsh and more palatable, increase the numbers of children and young adults who start smoking, make cigarettes more addictive and quitting more difficult, and have disproportionate effects on youth, African-Americans, and women. Halting CKD progression to ESRD requiring dialysis or transplantation remains the primary aspiration of the renal community. The development and qualification of biomarkers that could be used as surrogate endpoints 32 within an accelerated approval process for anti-CKD progression agents could enable rapid availability of effective therapeutic agents targeting this critical unmet need.
The FDA has created a mechanism that allows promising biomarkers to be evaluated for fitness-for-use in regulatory decision-making. 28 The medical community has responded by organizing consortia to acquire and evaluate data required for regulatory review. Progress will depend on adequate resourcing so that novel tools can be evaluated, reviewed, approved, and used in timely fashion. The 21 st Century Cures legislation and user fees include substantial support for FDA to contribute its part. The communities for these diseases now need to respond by building consortia and developing needed evidence.
Specific Therapeutic-Area Priorities Cardiovascular Disease
The cardiovascular community has prioritized other initiatives such as implementing new healthcare delivery systems to provide access to novel therapies and evidence-based practice;
reauthorization of user fees to support funding for medical product review, regulatory science, and evidence generation; and creating an innovation-friendly environment with appropriate patient protections ( Table 2 ).
Cardiovascular groups support efforts to lower sodium intake toward a goal of <2300 mg/day. Given controversy regarding optimal sodium intake (especially for patients with cardiovascular disease) and the absence of high-quality RCTs measuring major cardiovascular outcomes, 33 a mortality-based RCT of sodium reduction advice should be a priority. Mandatory sodium limits in prepared and processed foods should also be considered.
Endocrine Health
Recent Although disease pathophysiology differs between pediatric and adult patients, 46 ,47 Safety and efficacy data often are not generated for children, which affects treatment recommendations and access to therapy. For example, there are 14 FDA-approved targeted therapies for pulmonary arterial hypertension in adults but none approved for long-term pediatric use. Effective approaches to encouraging and incentivizing pediatric pulmonary drug development are needed.
A third area of concern is the impact of multidrug-resistant tuberculosis and resistant pathogens leading to severe pneumonias and sepsis. The growth of antibiotic resistance is outpacing new antibiotic development, and addressing different resistance mechanisms will require multiple new antibiotics in a wide variety of classes.
Renal Disease
The American Society of Nephrology, the FDA, and >75 member organizations and companies established the Kidney Health Initiative (KHI), a public-private partnership seeking to enhance innovation and patient safety in kidney care. [48] [49] [50] [51] In 2014, Medicare paid $26.1B to care for 428,000 hemodialysis patients. 52 However, the current 5-year survival rate for these patients is only 41.5%, significantly worse than most forms of cancer. Hemodialysis currently adds only a fraction of the possible value to overall healthcare, with value defined as outcomes/cost.
Accordingly, the construct of care within hemodialysis units (HDUs) presents opportunities to perform high-quality studies that could improve hemodialysis value. The HDU may be an ideal setting for pragmatic trials focused on process-of-care issues, such as those related to potassium flux, fluid removal, anticoagulation, and sudden cardiac death. Important advantages of the HDU for such an approach include: 1) thrice weekly patient availability, 2) low dropout rate, 3) ease of drawing blood samples during hemodialysis, 4) data collection that is reasonably uniform across dialysis providers, and 5) the ability to perform cluster randomization at the level of the HDU itself, which may or may not require formal written informed consent.
This approach is illustrated by the Time to reduce Mortality in End-stage renal disease (TiME) trial. TiME used cluster randomization at the HDU level to evaluate whether increasing hemodialysis duration from 4-4.25 hours could show benefit for mortality, hospitalization, and health-related QOL. This information is routinely collected in HDUs, thus substantially reducing research costs.
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Morbidity and mortality is primarily driven by causes indirectly triggered by renal disease, particularly cardiovascular disease. 52 Despite this, 57% of cardiovascular outcome studies excluded patients with CKD. 54, 55 Efforts by the community and patient groups to highlight this disconnect, combined with recommendations from federal agencies on the need to include CKD/ESRD patients in trials (similar to those governing inclusion of women, children, and minorities) could change prevailing mindsets on this issue. 56 In some cases, joint enrollment in cardiovascular outcomes trials is reasonable, while in other cases, specific trials in this growing population of CKD patients at risk of poor cardiovascular outcomes will be necessary.
"Dialysis keeps you alive but does not allow you to live." The renal community, particularly our patients, believes this to be a true characterization of dialysis, which has remained essentially unchanged for 2 decades. KHI and the FDA submitted a commitment statement to the White House Organ Summit on Organ Transplantation 57 in June 2016 to "initiate the development of a roadmap that will describe scientific, technical, and regulatory milestones needed to achieve the goal of creating a bio-artificial or bioengineered alternative to dialysis as renal replacement therapy." This roadmap engages all stakeholders to incentivize innovation and financial investment in this neglected area. 58 Although the nutrition facts label announced by FDA in May 2016 includes information on potassium and calcium, further attention should be paid to phosphorous. High phosphorous levels are linked to mortality in hemodialysis patients, 59 that now appears to extend to persons with normal kidney function. 60 A problematic issue is high levels of phosphorous resulting from use as an additive in processed food. 61 Because processed foods are typically cheaper, and many patients with CKD/ESRD are economically disadvantaged, including phosphorous on food labels could provide particular benefit for such patients, as well as for the general population.
Involving renal patients throughout the product development lifecycle, from identification of patient-centric issues, to patient-reported outcomes, to postmarketing input, is critically important. For example, the ability to travel while on hemodialysis often scores at the top of a list of important issues for patients, while ranking near the bottom on physician lists. 
FDA Role
The FDA supports an increasing emphasis on new approaches spanning organ systems and characterized by cross-center collaboration and communication. The agency has long been concerned about the relative lack of investment in therapeutic development in chronic diseases. 3 Adapting to a new information ecosystem that includes electronic health records, claims data, quality registries, and wearable devices presents critical issues in terms of ensuring evidence generation at costs that encourage investment in innovation. FDA can also play a role in stimulating new therapies through novel initiatives, such as biomarker qualification, use of novel or patient reportend endpoints, or expedited pathways for approval. 63 With regard to tobacco, the FDA has made great progress in finalizing the deeming rule; however, much remains to be done.
Finally, patient engagement is a high priority, as highlighted by the Center for Devices and Radiologic Health designating this as a strategic focus in 2016. 64 These discussions underscore the importance of including all stakeholders in efforts to strengthen science and advance new therapies.
Conclusions
Although the groups represented in this meeting focused on specific disease areas, the concept of a "multimorbidity continuum" emerged.  Provide support and resources through existing research consortia to apply advanced biological, computational, and statistical methods in identifying biomarkers that can be integrated into the regulatory framework Fig. 1 
